{"id":"bagrosin","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:34:34.401949","allNames":["bagrosin sodium","bagrosin"],"offLabel":[],"synonyms":["bagrosin sodium","bagrosin"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and bagrosin is a key that fits into one of those locks. When it binds, it can either unlock a new pathway for a healthy process or block a pathway that's causing a problem. However, since the target of bagrosin is unknown, we can't be sure exactly how it works.","oneSentence":"Bagrosin is a small molecule that works by binding to a specific target, although the exact mechanism is unknown.","technicalDetail":"Bagrosin's mechanism of action is likely to involve binding to a specific protein or receptor, although the exact molecular details are unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3778","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bagrosin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:49:03.410824","biosimilars":[],"competitors":[],"genericName":"bagrosin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(5)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"T3472PM20M","CHEBI":"CHEBI:135208","UMLSCUI":"C5773132","PUBCHEM_CID":"21893707"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":5,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Sep 29","pmid":"41021189","title":"Exploring drug repurposing for PAK2 inhibition: a systematic virtual screening of FDA-approved drugs against cancer.","journal":"Discover oncology"},{"date":"2024 Nov 29","pmid":"39613779","title":"Exploring PDK3 inhibition in lung cancer through drug repurposing for potential therapeutic interventions.","journal":"Scientific reports"},{"date":"2022 Mar","pmid":"33103586","title":"High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein.","journal":"Journal of biomolecular structure & dynamics"},{"date":"1957 Dec 6","pmid":"13503578","title":"[Treatment of epilepsy with bagrosin-sodium].","journal":"Medizinische Klinik"},{"date":"1956 Dec 22","pmid":"13399708","title":"[Treatment of childlike epilepsy with bagrosin, or bagrosin sodium].","journal":"Die Medizinische"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"bagrosin","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Bagrosin is a small molecule modality developed by an unknown entity, currently owned by an unknown entity. Its target and drug class are unknown, and it has not been approved by the FDA for any indications. The commercial status of bagrosin is unclear, and it is not known whether it is patented or available as a generic medication. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also lacking. As a result, there is limited information available on the safety and efficacy of bagrosin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}